UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 416, 2026

FENNEC PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

001-32295

(Commission File Number)

British Columbia, Canada

20-0442384

(State or other jurisdiction of

incorporation)

(I.R.S. Employer Identification No.)

PO Box 13628, 68 TW Alexander Drive,

Research Triangle Park, NC

27709

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (919) 636-4530

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


	☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


	☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


	☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


	☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12 of the Act:


Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common shares, no par value	FENC	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 8.01.	Other Events.

On March 416, 2026, Fennec Pharmaceuticals Inc. (the “Company”) ~~announced~~entered ~~that~~into a License Agreement with Cipla Limited and Cipla USA, Inc. (together, “Cipla”) to resolve the ~~Tampa~~litigation ~~General~~between ~~Hospital~~the ~~Cancer~~Company ~~Institute~~and isCipla ~~initiating~~relating ato ~~study~~Cipla’s ~~evaluating~~application to the ~~real-world~~U.S. ~~clinical~~Food ~~utility~~and Drug Administration to market a generic version of the Company’s PEDMARK® (sodium thiosulfate injection) product, captioned Fennec Pharmaceuticals Inc. v. Cipla Limited and Cipla USA, Inc., C.A. No. 2:23-cv-00123-JKS-MAH (~~PEDMARK®~~D.N.J.). inPursuant ~~reducing~~to the ~~risk~~terms of ~~ototoxicity~~the License Agreement, the lawsuit will be dismissed, each party will bear its own costs in ~~adolescent~~connection ~~and~~with ~~young~~the ~~adult~~litigation, and ~~adult~~Cipla ~~cancer~~has ~~patients~~agreed ~~receiving~~not ~~cisplatin-based~~to ~~chemotherapy~~enter the U.S. market with its generic sodium thiosulfate product until September 1, 2033, subject to earlier entry under specified circumstances.

AOn ~~copy~~March of16, 2026, the Company issued a press release isannouncing ~~furnished~~the asLicense ~~Exhibit~~Agreement ~~99.1~~and toresolution ~~this~~of ~~Current~~the ~~Report~~Cipla onlitigation ~~Form~~a ~~8-K~~copy of which is furnished herewith as Exhibit 99.1.

The information contained in this Item 8.01, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor incorporated by reference into any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.


Item 9.01	Financial Statements and Exhibits.


	(d)	Exhibits.


Exhibit No.	Description
Exhibit 99.1	Press Release dated March 416, 2026
Exhibit 104	Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


		FENNEC PHARMACEUTICALS INC.
Date March 4, 2026	By:	/s/ Robert Andrade
Date March 16, 2026	By:	/s/ Robert Andrade
		Robert AndradeChief Financial Officer

Filing Compare · FENNEC PHARMACEUTICALS INC.